Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:

NCT ID: NCT05250869 Completed - Lymphoma Clinical Trials

Comparative Quantification of MTX and Its Metabolites Post Glucarpidase

Start date: July 6, 2022
Phase:
Study type: Observational

Acidification (i.e., addition of hydrochloric acid) of plasma samples from patients who have received Glucarpidase post high-dose MTX treatment is regarded as a necessary preanalytic step to avoid further in vitro enzymatic cleavage of MTX. However, it is unclear whether this acidification step is essential. A comparative study, which evaluates concentrations of MTX and its metabolites in paired (acidified versus non-acidified) plasma samples, has not yet been performed. Processing plasma samples without acidification would facilitate quantification of MTX, including plasma samples from patients treated at centers without adequate laboratory facilities.

NCT ID: NCT05166135 Completed - Clinical trials for Acute Myeloid Leukemia

Latin American Real-world Study in Acute Leukemia

LOYAL
Start date: December 10, 2021
Phase:
Study type: Observational

The objective of the study is to describe the current epidemiology, treatment patterns, outcomes and healthcare resource use of adult patients diagnosed with relapsed/refractory (R/R) B-cell ALL and de novo AML in 4 Latin American countries.

NCT ID: NCT05093192 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Chronic lymphocytic leukaemia (CLL) is the most common adult blood cancer in the United Kingdom. CLL means that many cancer cells appear in the blood, bone marrow and other tissues, for example, the spleen where some blood cells reside. Most patients with CLL have been diagnosed by chance, have no symptoms as a result of CLL, and do not need urgent treatment. However, when the cancer cells build up, people experience symptoms of CLL, and treatment is required. One of the current treatments for CLL is chemo-immunotherapy, that targets and kills cancer cells in the blood. However, this treatment does not kill all cancer cells. Some cancer cells survive by 'hiding' in the bone marrow and tissues, like the spleen, where the treatment cannot get to, this is called minimal residual disease (MRD). MRD eventually builds up and patients experience symptoms of CLL again. New approaches to detect and treat MRD are needed. Research has shown, that the number of blood cells, increases after exercise and that many of these blood cells come from the bone marrow and other tissues. This study will investigate if exercise can move CLL cancer cells that are 'hiding' in the bone marrow and other tissues into the blood, thus improving the detection of MRD. By moving cancer cells into blood, the investigators also think this will improve the way chemo-immunotherapy works. In this study, the investigators will investigate the number of cancer and natural killer (NK) cells in the blood after exercise, in three different groups of people with CLL: before treatment; during treatment; and after treatment has finished.

NCT ID: NCT05086354 Completed - Childhood Cancer Clinical Trials

Examining a Training Program for for Acute Lymphoblastic Leukemia Childhood Cancer Survivors

JUMP
Start date: March 16, 2018
Phase: N/A
Study type: Interventional

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with the peak incidences occurring in children two to five years of age. Children with ALL received neurotoxic chemotherapy agents for two to three years that causes decreased distal muscle strength and poor timing of muscle activation. After completion of medical treatment, ALL childhood cancer survivors (ALL CCS) are more likely to have an inactive lifestyle, resulting in life-long gross motor proficiency differences compared to their peers. ALL CCS typically do not utilize physical therapists' expertise after medical treatment has been completed. There are limited physical therapy (PT) intervention studies for ALL CCS.

NCT ID: NCT05045443 Completed - Clinical trials for Acute Lymphoblastic Leukemia, Pediatric

Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia

CurcumPedALL
Start date: August 22, 2021
Phase: Phase 2
Study type: Interventional

Assessment of of the biological effects of curcumin on microbiota in children with acute lymphoblastic leukemia

NCT ID: NCT05032716 Completed - Clinical trials for Acute Lymphoblastic Leukemia, Pediatric

EFFECT OF TREADMILL TRAINING ON BALANCE AFTER CHEMOTHERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Start date: May 5, 2021
Phase: N/A
Study type: Interventional

Purpose: The present research was conducted to study the effect of treadmill training on balance after chemotherapy in children with acute lymphoblastic leukemia. Subjects and Methods: Forty children with acute lymphoblastic leukemia included in the current research ranged of age from 8 to 12 years. The children participated in this study were assigned randomly into two equal number groups (A and B). Group (A) includes 20 children who received balance exercises, while group (B) includes 20 children who received the same balance exercises of group (A) and treadmill training. The treatment program was applied three sessions per week (60 min for every session) for 8 weeks. Balance Master System and Biodex Balance System were used to evaluate balance of all children in the three groups before and after the treatment program.

NCT ID: NCT05007860 Completed - Clinical trials for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia

Start date: July 16, 2020
Phase:
Study type: Observational

Assessment of SARS-CoV2 (mRNA and adenovirus-based vaccines) and Conjugated Pneumococcal (PCV13) in Patients with Chronic Lymphocytic Leukemia

NCT ID: NCT04964908 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia

CREEK
Start date: December 3, 2021
Phase:
Study type: Observational

A Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia A retrospective, multi-centre, observational study to describe disease characteristics, treatment patterns, treatment-related outcomes, and resource utilization for Chronic Lymphocytic Leukemia (CLL) patients in multiple international regions

NCT ID: NCT04956666 Completed - Clinical trials for Acute Lymphoblastic Leukemia

A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)

ALL
Start date: June 15, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide treatment with lyophilized S95014 in pediatric patients with ALL who completed the CL2-95014-002 study during the induction phase and who are clinically benefitting from S95014 without major toxicity.

NCT ID: NCT04954326 Completed - Clinical trials for Acute Lymphoblastic Leukemia

A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)

ALL
Start date: May 7, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the pharmacokinetics (PK) of both lyophilized and liquid S95014 formulations during the induction phase after a single IV dose in newly diagnosed paediatric patients with ALL